Delivery Order SPE2DB20D3303-SPE2DB25FA1UG
- Not listed
- The Defense Logistics Agency awarded a $3,796.45 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $27,220.72 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 21, 2025, with completion targeted for July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical supplier...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,943.19 on July 18, 2025, for the supply of Xeljanz XR 11 mg tablets (30-count units). This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract valued at $5,239.68 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of XELJANZ XR 11 MG TABLET 30S. This order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to AmerisourceBergen Drug Corp by DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,118.90 contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a prescription medication. The contract has an ultimate completion date of January 10, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
- The Defense Logistics Agency awarded a $4,455.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units), with an ultimate completion date of July 21, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. The delivery order represents a...
- This is a $3,038.52 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of XELJANZ XR 11 MG TABLET and has a period of performance through June 17, 2025. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET UU 30S. The firm-fixed-price contract, valued at $32,975.65, has an ultimate completion date of May 28, 2025. The award is not set-aside and is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC enables the company...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,621.77, is for the provision of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product. The contract has a period of performance through July 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $15,793.76, is for the supply of XELJANZ XR 11 MG tablets. The order has a completion date of May 13, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA1UGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,828.26 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. The contract is classified as a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide. XELJANZ XR is a prescription medication used for rheumatoid arthritis and other inflammatory conditions, reflecting the company's role as a critical pharmaceutical distributor for federal medical procurement supporting Defense Health Agency, the U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 7/25/25 |